73326-20-2

Basic information

• Product Name: 2-bromo-N-1,3-thiazol-2-ylacetamide
• Synonyms: 2-bromo-N-1,3-thiazol-2-ylacetamide;acetamide, 2-bromo-N-2-thiazolyl-;2-bromo-N-(1,3-thiazol-2-yl)ethanamide;2-bromo-N-(2-thiazolyl)acetamide;2-bromo-N-thiazol-2-yl-acetamide;N-Bromacetyl-2-amino-thiazol
• CAS NO: 73326-20-2
• Molecular Formula: C₅H₅BrN₂OS
• Molecular Weight: 221.077
• Mol File: 73326-20-2.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Density: 1.867g/cm³
• Refractive Index: 1.679
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-bromo-N-1,3-thiazol-2-ylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N-1,3-thiazol-2-ylacetamide(73326-20-2)
• EPA Substance Registry System: 2-bromo-N-1,3-thiazol-2-ylacetamide(73326-20-2)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 73326-20-2(Hazardous Substances Data)

Usage

General Description

2-bromo-N-1,3-thiazol-2-ylacetamide is a chemical compound with the molecular formula C6H6BrN2OS. It is a derivative of thiazole and is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. 2-bromo-N-1,3-thiazol-2-ylacetamide contains a bromine atom and a thiazole ring, making it useful for various chemical reactions and applications. It can also act as a building block for the synthesis of more complex organic compounds. 2-bromo-N-1,3-thiazol-2-ylacetamide is a valuable chemical in the field of organic synthesis and can be utilized in the production of a wide range of products.

InChI:InChI=1/C5H5BrN2OS/c6-3-4(9)8-5-7-1-2-10-5/h1-2H,3H2,(H,7,8,9)

Upstream product

• 96-50-4 2-thiazolylamine 
• 598-21-0 2-Bromoacetyl bromide 
• 22118-09-8 2-bromoacetyl chloride 

Relevant articles and documents

Identifying Novel Anti-Osteoporosis Leads with a Chemotype-Assembly Approach

In this paper, we applied a chemotype-assembly approach for ligand-based drug discovery (LBDD) to discover novel anti-osteoporosis leads. With this new approach, we identified 12 chemotypes and derived 18 major chemotype assembly rules from 245 known anti-osteoporosis compounds. Then, we selected 19 compounds from an in-house compound library using chemotype-assembly approach for anti-osteoporosis assays, which resulted in 13 hits. Based on structural features in these 13 compounds, we synthesized 50 possible anti-osteoporosis compounds from the anti-osteoporosis chemotypes by means of click chemistry techniques and discovered a compound (10a, IC50 = 2 nM) with nanomolar activity. Compound 10a was then proved to be an anti-osteoporosis lead since it can prevent bone loss in vivo.

HETEROCYCLIC COMPOUNDS AS CLASS II PHOSPHOINOSITIDE 3-KINASE INHIBITORS

The present application relates to compounds of formula (1) and their use as medicament, in particular for the treatment of a medical condition associated with defective PI3K signalling.

Targeting mycobacterium protein tyrosine phosphatase B for antituberculosis agents

Protein tyrosine phosphatases are often exploited and subverted by pathogenic bacteria to cause human diseases. The tyrosine phosphatase mPTPB from Mycobacterium tuberculosis is an essential virulence factor that is secreted by the bacterium into the cytoplasm of macrophages, where it mediates mycobacterial survival in the host. Consequently, there is considerable interest in understanding the mechanism by which mPTPB evades the host immune responses, and in developing potent and selective mPTPB inhibitors as unique antituberculosis (antiTB) agents. We uncovered that mPTPB subverts the innate immune responses by blocking the ERK1/2 and p38 mediated IL-6 production and promoting host cell survival by activating the Akt pathway. We identified a potent and selective mPTPB inhibitor I-A09 with highly efficacious cellular activity, from a combinatorial library of bidentate benzofuran salicylic acid derivatives assembled by click chemistry. We demonstrated that inhibition of mPTPB with I-A09 in macrophages reverses the altered host immune responses induced by the bacterial phosphatase and prevents TB growth in host cells. The results provide the necessary proof-of-principle data to support the notion that specific inhibitors of the mPTPB may serve as effective antiTB therapeutics.